Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Laurus Investment Counsel Inc.

Laurus Investment Counsel Inc. increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 79,150 shares of the medical research company's stock after purchasing an additional 7,435 shares during the quarter. Charles River Laboratories International makes up approximately 7.5% of Laurus Investment Counsel Inc.'s portfolio, making the stock its 5th largest position. Laurus Investment Counsel Inc. owned about 0.15% of Charles River Laboratories International worth $14,611,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board increased its position in Charles River Laboratories International by 77.8% in the 2nd quarter. Public Sector Pension Investment Board now owns 1,982 shares of the medical research company's stock worth $409,000 after purchasing an additional 867 shares during the last quarter. Cetera Investment Advisers increased its holdings in Charles River Laboratories International by 2.4% in the second quarter. Cetera Investment Advisers now owns 9,969 shares of the medical research company's stock worth $2,059,000 after buying an additional 229 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Charles River Laboratories International in the second quarter worth approximately $5,422,000. Massmutual Trust Co. FSB ADV raised its position in Charles River Laboratories International by 4.5% during the third quarter. Massmutual Trust Co. FSB ADV now owns 1,842 shares of the medical research company's stock valued at $363,000 after acquiring an additional 79 shares in the last quarter. Finally, Czech National Bank lifted its stake in Charles River Laboratories International by 7.1% in the third quarter. Czech National Bank now owns 10,517 shares of the medical research company's stock valued at $2,072,000 after acquiring an additional 701 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a "sell" rating and a $151.00 price target on the stock. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. CLSA downgraded Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a research note on Monday, November 18th. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Finally, The Goldman Sachs Group reduced their target price on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $204.38.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares of the company's stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded down $0.69 during mid-day trading on Friday, reaching $164.88. The company had a trading volume of 623,019 shares, compared to its average volume of 867,492. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $8.43 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 6.13 and a beta of 1.38. The company has a 50 day moving average of $184.15 and a 200-day moving average of $195.45. Charles River Laboratories International, Inc. has a 52 week low of $159.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. During the same quarter last year, the company earned $2.72 earnings per share. The firm's revenue was down 1.6% on a year-over-year basis. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).